Repligen Corp (NASDAQ:RGEN)
| 7.70 Data as of 12:10pm ET |  -0.22 / -2.78%Today’s Change | 3.78 Today|||52-Week Range 9.65 | +22.61% Year-to-Date |
Latest RGEN News | Press Releases
| Why Repligen Is Ready to Rebound Jun 18 / MotleyFool.com |
Today’s Trading
| Previous close | 7.92 |
| Today’s open | 7.91 |
| Day’s range | 7.65 - 7.94 |
| Volume | 72,004 |
| Average volume (3 months) | 352,494 |
| Market cap | $249.0M |
| Dividend yield | -- |
Data as of 12:10pm ET, 06/19/2013
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +24.44% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | +99.15% |
| P/E ratio | 16.0 |
| Price/Sales | 3.12 |
| Price/Book | 2.94 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PGNXProgenics Pharmaceut... | +0.01 | +0.10% |
| CNDOCoronado Biosciences... | -0.40 | -4.58% |
| TNIBTNI BioTech Inc | 0.00 | 0.00% |
| STSIStar Scientific Inc | -0.04 | -2.76% |
Data as of 12:21pm ET, 06/19/2013
Financials
| Next reporting date | November 7, 2013 |
| EPS forecast (this quarter) | $0.10 |
| Annual revenue (last year) | $62.3M |
| Annual profit (last year) | $14.2M |
| Net profit margin | 22.73% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Walter C. Herlihy, PhD |
Senior Vice President- Global Operations Daniel P. Witt, PhD |
Corporate headquarters Waltham, Massachusetts |
Forecasts
